Janux Therapeutics, Inc.
NASDAQ: JANX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- David Alan Campbell
- Employees
- 91
- Headquarters
- San Diego, United States
- IPO year
- 2021
- Market cap
- $892.8M
- Website
- https://www.januxrx.com
Loading JANX…
Loading profile data…Frequently asked questions about JANX
What does Janux Therapeutics, Inc. (JANX) do?
Janux Therapeutics, Inc. is a biopharmaceutical company dedicated to developing innovative cancer therapies. The firm leverages its proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to create treatments designed to activate the body's T cells to fight tumors. Currently, Janux has several promising TRACTr product candidates...
Where does JANX trade?
Janux Therapeutics, Inc. (JANX) trades on the NASDAQ Global Market.
What sector is JANX in?
Janux Therapeutics, Inc. (JANX) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Janux Therapeutics, Inc.?
David Alan Campbell is the chief executive officer of Janux Therapeutics, Inc. (JANX).
Where is Janux Therapeutics, Inc. headquartered?
Janux Therapeutics, Inc. is headquartered in United States.
Does JANX pay a dividend?
Janux Therapeutics, Inc. (JANX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did JANX go public?
Janux Therapeutics, Inc. (JANX) completed its initial public offering in 2021.